Bristol-Myers Squibb (NYSE:BMY) SVP Sells $38,934.00 in Stock

Bristol-Myers Squibb (NYSE:BMY) SVP Phil M. Holzer sold 700 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at $654,091.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock opened at $54.74 on Friday. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $56.80. The stock has a market capitalization of $111.02 billion, a P/E ratio of -15.25, a P/E/G ratio of 12.39 and a beta of 0.44. The firm’s 50-day moving average is $51.69 and its two-hundred day moving average is $46.72. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. During the same period last year, the company earned $2.00 EPS. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. Equities analysts predict that Bristol-Myers Squibb will post 0.9 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.38%. Bristol-Myers Squibb’s payout ratio is currently -66.85%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BMY. UBS Group increased their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, October 9th. Barclays increased their price target on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a report on Monday, October 7th. TD Cowen increased their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a report on Monday, October 7th. Jefferies Financial Group increased their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research note on Wednesday, August 28th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $53.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. First City Capital Management Inc. raised its holdings in Bristol-Myers Squibb by 11.3% in the third quarter. First City Capital Management Inc. now owns 20,945 shares of the biopharmaceutical company’s stock valued at $1,084,000 after buying an additional 2,120 shares during the period. Prospera Financial Services Inc raised its stake in shares of Bristol-Myers Squibb by 40.0% during the third quarter. Prospera Financial Services Inc now owns 73,255 shares of the biopharmaceutical company’s stock valued at $3,791,000 after purchasing an additional 20,916 shares during the period. Verity & Verity LLC purchased a new stake in shares of Bristol-Myers Squibb during the third quarter valued at approximately $226,000. Meeder Asset Management Inc. raised its stake in shares of Bristol-Myers Squibb by 93.8% during the third quarter. Meeder Asset Management Inc. now owns 31,672 shares of the biopharmaceutical company’s stock valued at $1,639,000 after purchasing an additional 15,329 shares during the period. Finally, OneAscent Financial Services LLC purchased a new stake in shares of Bristol-Myers Squibb during the third quarter valued at approximately $458,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.